Clinical Trial Update: Russian Registry of Patients With nAMD

View source ↗

Summary

A Russian registry trial for neovascular age-related macular degeneration sponsored by Novartis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovascular Age-Related Macular Degeneration | Status: TERMINATED